6 ms·
Exactly. I know if medication were to be developed, checking "are GDF15 levels significantly lowered" would be part of the trials. But how often does the medic
by croshan 3y ago
Exactly. I know if medication were to be developed, checking "are GDF15 levels significantly lowered" would be part of the trials.
But how often does the medication development process check the result we care about: "does this medication then go on to reduce the chance of dementia?"
- wbl 3y agoAlways. Secondary endpoints are heavily disfavored in FDA approval.